Drug reference
Type 2 diabetes mellitus [not controlled by metformin and/or a sulfonylurea with either empagliflozin or linagliptin] ▶BY MOUTH ▶Adult 18–74 years: 10/5 mg once daily, increased to 25/5 mg once daily if necessary and if tolerated ▶Adult 75 years and over: Initiation not recommended
PDF page 767
DUE TO INTERACTIONS ▶Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced. DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg of empagliflozin/linagliptin.
PDF page 767
Scottish Medicines Consortium (SMC) decisions SMC No. SMC1236/17 The Scottish Medicines Consortium has advised (August 2019) that empagliflozin with linagliptin (Glyxambi ®) is accepted for restricted use within NHS Scotland in adults with type 2 diabetes mellitus: . to improve glycaemic control when metformin and/or sulphonylurea, and one of the monocomponents of Glyxambi ® do not provide adequate glycaemic control, or . when already being treated with the free combination of empagliflozin and linagliptin. Its use is restricted in line with previous advice on empagliflozin and linagliptin.
PDF page 767
→Appendix 1: empagliflozin. linagliptin
PDF page 767
There can be variation in the licensing of different medicines containing the same drug. Tablet A ▶Glyxambi (Boehringer Ingelheim Ltd) Linagliptin 5 mg, Empagliflozin 10 mg Glyxambi 10mg/5mg tablets | 28 tablet P £55.88 DT = £55.88 Linagliptin 5 mg, Empagliflozin 25 mg Glyxambi 25mg/5mg tablets | 28 tablet P £55.88 DT = £55.88
PDF page 767
Missed doses Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
PDF page 767
10/5 mg once daily, increased to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 767
Initiation not recommended
First-line fragment. Read the complete Indications and Dose section above.
PDF page 767
